525 related articles for article (PubMed ID: 30790064)
21. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.
Curtin JF; King GD; Candolfi M; Greeno RB; Kroeger KM; Lowenstein PR; Castro MG
Curr Top Med Chem; 2005; 5(12):1151-70. PubMed ID: 16248789
[TBL] [Abstract][Full Text] [Related]
22. New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors.
De Felice F; Musio D; Cassese R; Gravina GL; Tombolini V
Curr Cancer Drug Targets; 2017; 17(3):282-289. PubMed ID: 27528363
[TBL] [Abstract][Full Text] [Related]
23. Current vaccine trials in glioblastoma: a review.
Xu LW; Chow KK; Lim M; Li G
J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
[TBL] [Abstract][Full Text] [Related]
24. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological strategies for improving the prognosis of glioblastoma.
Raj D; Agrawal P; Gaitsch H; Wicks E; Tyler B
Expert Opin Pharmacother; 2021 Oct; 22(15):2019-2031. PubMed ID: 34605345
[No Abstract] [Full Text] [Related]
26. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
27. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
[TBL] [Abstract][Full Text] [Related]
28. Therapy for glioblastoma: is it working?
Zanders ED; Svensson F; Bailey DS
Drug Discov Today; 2019 May; 24(5):1193-1201. PubMed ID: 30878561
[TBL] [Abstract][Full Text] [Related]
29. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
30. Emerging therapies for glioblastoma: current state and future directions.
Rong L; Li N; Zhang Z
J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
[TBL] [Abstract][Full Text] [Related]
31. Emerging patents in the therapeutic areas of glioma and glioblastoma.
Harris M; Svensson F; Kopanitsa L; Ladds G; Bailey D
Expert Opin Ther Pat; 2018 Jul; 28(7):573-590. PubMed ID: 29950117
[TBL] [Abstract][Full Text] [Related]
32. Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives.
Abadi B; Yazdanpanah N; Nokhodchi A; Rezaei N
Adv Drug Deliv Rev; 2021 Dec; 179():114035. PubMed ID: 34740765
[TBL] [Abstract][Full Text] [Related]
33. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives.
Sener U; Ruff MW; Campian JL
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806051
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
[TBL] [Abstract][Full Text] [Related]
36. Tumor Vaccines for Malignant Gliomas.
Srinivasan VM; Ferguson SD; Lee S; Weathers SP; Kerrigan BCP; Heimberger AB
Neurotherapeutics; 2017 Apr; 14(2):345-357. PubMed ID: 28389997
[TBL] [Abstract][Full Text] [Related]
37. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
[TBL] [Abstract][Full Text] [Related]
38. Temozolomide for immunomodulation in the treatment of glioblastoma.
Karachi A; Dastmalchi F; Mitchell DA; Rahman M
Neuro Oncol; 2018 Nov; 20(12):1566-1572. PubMed ID: 29733389
[TBL] [Abstract][Full Text] [Related]
39. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
40. The Role of Checkpoint Inhibitors in Glioblastoma.
Desai K; Hubben A; Ahluwalia M
Target Oncol; 2019 Aug; 14(4):375-394. PubMed ID: 31290002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
